{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:28:13Z","timestamp":1791260893484,"version":"4.1.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070175"],"award-info":[{"award-number":["82070175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11864-025-01293-w","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:52:31Z","timestamp":1738385551000},"page":"142-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Qingyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhe","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-5150","authenticated-orcid":false,"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"12","key":"1293_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","volume":"20","author":"A Sindel","year":"2019","unstructured":"Sindel A, et al. Marginal zone lymphoma: state-of-the-art treatment. Curr Treat Options Oncol. 2019;20(12):90. https:\/\/doi.org\/10.1007\/s11864-019-0687-5.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"1293_CR2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/blood-2013-07-515155","volume":"123","author":"A Xochelli","year":"2014","unstructured":"Xochelli A, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014;123(8):1199\u2013206. https:\/\/doi.org\/10.1182\/blood-2013-07-515155.","journal-title":"Blood"},{"issue":"2","key":"1293_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1523-5378.2006.00382.x","volume":"11","author":"T Akamatsu","year":"2006","unstructured":"Akamatsu T, et al. Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter. 2006;11(2):86\u201395. https:\/\/doi.org\/10.1111\/j.1523-5378.2006.00382.x.","journal-title":"Helicobacter"},{"issue":"3","key":"1293_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/path.1984","volume":"209","author":"E Chanudet","year":"2006","unstructured":"Chanudet E, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol. 2006;209(3):344\u201351. https:\/\/doi.org\/10.1002\/path.1984.","journal-title":"J Pathol"},{"issue":"8","key":"1293_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","volume":"24","author":"L Cerroni","year":"1997","unstructured":"Cerroni L, et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457\u201361. https:\/\/doi.org\/10.1111\/j.1600-0560.1997.tb01318.x.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"1293_CR6","doi-asserted-by":"publisher","first-page":"e2016006","DOI":"10.4084\/mjhid.2016.006","volume":"8","author":"S Perrone","year":"2016","unstructured":"Perrone S, et al. Infectious aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016006. https:\/\/doi.org\/10.4084\/mjhid.2016.006.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"1293_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdl388","volume":"18","author":"L Arcaini","year":"2007","unstructured":"Arcaini L, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18(2):346\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdl388.","journal-title":"Ann Oncol"},{"issue":"1","key":"1293_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jnci\/djj004","volume":"98","author":"KE Smedby","year":"2006","unstructured":"Smedby KE, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51\u201360. https:\/\/doi.org\/10.1093\/jnci\/djj004.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1293_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/jcem.87.1.8156","volume":"87","author":"C Thieblemont","year":"2002","unstructured":"Thieblemont C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002;87(1):105\u201311. https:\/\/doi.org\/10.1210\/jcem.87.1.8156.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1293_CR10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.V90.2.766","volume":"90","author":"B Royer","year":"1997","unstructured":"Royer B, et al. Lymphomas in patients with Sjogren\u2019s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90(2):766\u201375.","journal-title":"Blood"},{"issue":"1","key":"1293_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.19238","volume":"204","author":"E Flospergher","year":"2024","unstructured":"Flospergher E, et al. Primary central nervous system marginal zone lymphoma. Br J Haematol. 2024;204(1):31\u201344. https:\/\/doi.org\/10.1111\/bjh.19238.","journal-title":"Br J Haematol"},{"issue":"7","key":"1293_CR12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","volume":"54","author":"L Liu","year":"2013","unstructured":"Liu L, et al. Splenic marginal zone lymphoma: a population-based study on the 2001\u20132008 incidence and survival in the United States. Leuk Lymphoma. 2013;54(7):1380\u20136. https:\/\/doi.org\/10.3109\/10428194.2012.743655.","journal-title":"Leuk Lymphoma"},{"key":"1293_CR13","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909\u201318.","DOI":"10.1182\/blood.V89.11.3909"},{"issue":"10","key":"1293_CR14","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","volume":"25","author":"FI Camacho","year":"2001","unstructured":"Camacho FI, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25(10):1268\u201376. https:\/\/doi.org\/10.1097\/00000478-200110000-00007.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1293_CR15","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","volume":"100","author":"JI Chac\u00f3n","year":"2002","unstructured":"Chac\u00f3n JI, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648\u201354.","journal-title":"Blood"},{"issue":"6","key":"1293_CR16","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","volume":"95","author":"F Berger","year":"2000","unstructured":"Berger F, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95(6):1950\u20136.","journal-title":"Blood"},{"issue":"2","key":"1293_CR17","first-page":"194","volume":"26","author":"C Thieblemont","year":"2012","unstructured":"Thieblemont C, et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park). 2012;26(2):194\u2013202.","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"1293_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.13975","volume":"173","author":"AG Starr","year":"2016","unstructured":"Starr AG, et al. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. Br J Haematol. 2016;173(3):404\u201312. https:\/\/doi.org\/10.1111\/bjh.13975.","journal-title":"Br J Haematol"},{"key":"1293_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcancer.2016.07.003","volume":"39","author":"MQ Du","year":"2016","unstructured":"Du MQ. MALT lymphoma: A paradigm of NF-\u03baB dysregulation. Semin Cancer Biol. 2016;39:49\u201360. https:\/\/doi.org\/10.1016\/j.semcancer.2016.07.003.","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"1293_CR20","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"K Ekstr\u00f6m Smedby","year":"2008","unstructured":"Ekstr\u00f6m Smedby K, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029\u201338. https:\/\/doi.org\/10.1182\/blood-2007-10-119974.","journal-title":"Blood"},{"issue":"10","key":"1293_CR21","first-page":"995","volume":"9","author":"RK Brynes","year":"1996","unstructured":"Brynes RK, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol. 1996;9(10):995\u20131000.","journal-title":"Mod Pathol"},{"issue":"8","key":"1293_CR22","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1182\/blood.V85.8.2000.bloodjournal8582000","volume":"85","author":"AC Wotherspoon","year":"1995","unstructured":"Wotherspoon AC, et al. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood. 1995;85(8):2000\u20134.","journal-title":"Blood"},{"issue":"11","key":"1293_CR23","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1038\/sj.leu.2403122","volume":"17","author":"EM Murga Penas","year":"2003","unstructured":"Murga Penas EM, et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT\/MALT1 in MALT lymphomas. Leukemia. 2003;17(11):2225\u20139. https:\/\/doi.org\/10.1038\/sj.leu.2403122.","journal-title":"Leukemia"},{"issue":"6016","key":"1293_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1198946","volume":"331","author":"S Rosebeck","year":"2011","unstructured":"Rosebeck S, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science. 2011;331(6016):468\u201372. https:\/\/doi.org\/10.1126\/science.1198946.","journal-title":"Science"},{"issue":"11","key":"1293_CR25","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1182\/blood-2002-10-3236","volume":"101","author":"D Sanchez-Izquierdo","year":"2003","unstructured":"Sanchez-Izquierdo D, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood. 2003;101(11):4539\u201346. https:\/\/doi.org\/10.1182\/blood-2002-10-3236.","journal-title":"Blood"},{"issue":"17","key":"1293_CR26","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1111\/febs.13325","volume":"282","author":"IS Afonina","year":"2015","unstructured":"Afonina IS, et al. MALT1\u2013a universal soldier: multiple strategies to ensure NF-\u03baB activation and target gene expression. Febs j. 2015;282(17):3286\u201397. https:\/\/doi.org\/10.1111\/febs.13325.","journal-title":"Febs j"},{"issue":"23","key":"1293_CR27","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/blood-2014-01-553412","volume":"124","author":"M van Keimpema","year":"2014","unstructured":"van Keimpema M, et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-\u03baB to promote survival of human B cells. Blood. 2014;124(23):3431\u201340. https:\/\/doi.org\/10.1182\/blood-2014-01-553412.","journal-title":"Blood"},{"issue":"7","key":"1293_CR28","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2002-10-3167","volume":"101","author":"H Ye","year":"2003","unstructured":"Ye H, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003;101(7):2547\u201350. https:\/\/doi.org\/10.1182\/blood-2002-10-3167.","journal-title":"Blood"},{"issue":"4","key":"1293_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/sj.leu.2403644","volume":"19","author":"B Streubel","year":"2005","unstructured":"Streubel B, et al. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19(4):652\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2403644.","journal-title":"Leukemia"},{"issue":"16","key":"1293_CR30","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/jco.2006.05.6150","volume":"24","author":"X Sagaert","year":"2006","unstructured":"Sagaert X, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16):2490\u20137. https:\/\/doi.org\/10.1200\/jco.2006.05.6150.","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"1293_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12308-017-0302-2","volume":"10","author":"MI Schreuder","year":"2017","unstructured":"Schreuder MI, et al. Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. J Hematop. 2017;10(3\u20134):91\u2013107. https:\/\/doi.org\/10.1007\/s12308-017-0302-2.","journal-title":"J Hematop"},{"issue":"9","key":"1293_CR32","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41379-018-0064-0","volume":"31","author":"J Hyeon","year":"2018","unstructured":"Hyeon J, et al. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Mod Pathol. 2018;31(9):1418\u201328. https:\/\/doi.org\/10.1038\/s41379-018-0064-0.","journal-title":"Mod Pathol"},{"issue":"18","key":"1293_CR33","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1158\/1078-0432.Ccr-14-2759","volume":"21","author":"M Parry","year":"2015","unstructured":"Parry M, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174\u201383. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2759.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1293_CR34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1084\/jem.20120910","volume":"209","author":"MJ Kiel","year":"2012","unstructured":"Kiel MJ, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553\u201365. https:\/\/doi.org\/10.1084\/jem.20120910.","journal-title":"J Exp Med"},{"issue":"2","key":"1293_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/leu.2014.294","volume":"29","author":"R Piva","year":"2015","unstructured":"Piva R, et al. The Kr\u00fcppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29(2):503\u20137. https:\/\/doi.org\/10.1038\/leu.2014.294.","journal-title":"Leukemia"},{"issue":"5","key":"1293_CR36","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/leu.2014.330","volume":"29","author":"A Clipson","year":"2015","unstructured":"Clipson A, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29(5):1177\u201385. https:\/\/doi.org\/10.1038\/leu.2014.330.","journal-title":"Leukemia"},{"issue":"4","key":"1293_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1182\/blood.v99.4.1299","volume":"99","author":"P Algara","year":"2002","unstructured":"Algara P, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99(4):1299\u2013304. https:\/\/doi.org\/10.1182\/blood.v99.4.1299.","journal-title":"Blood"},{"issue":"9","key":"1293_CR38","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","volume":"116","author":"M Salido","year":"2010","unstructured":"Salido M, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116(9):1479\u201388. https:\/\/doi.org\/10.1182\/blood-2010-02-267476.","journal-title":"Blood"},{"issue":"1","key":"1293_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0002-9440(10)61691-4","volume":"159","author":"R Marasca","year":"2001","unstructured":"Marasca R, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol. 2001;159(1):253\u201361. https:\/\/doi.org\/10.1016\/s0002-9440(10)61691-4.","journal-title":"Am J Pathol"},{"issue":"2","key":"1293_CR40","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1073\/pnas.1013168108","volume":"108","author":"GT Hart","year":"2011","unstructured":"Hart GT, et al. Kr\u00fcppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci U S A. 2011;108(2):716\u201321. https:\/\/doi.org\/10.1073\/pnas.1013168108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"1293_CR41","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.1158\/1078-0432.Ccr-04-0803","volume":"10","author":"S W\u00f6hrer","year":"2004","unstructured":"W\u00f6hrer S, et al. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res. 2004;10(21):7179\u201381. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-0803.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1293_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.leu.2405068","volume":"22","author":"E Matutes","year":"2008","unstructured":"Matutes E, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487\u201395. https:\/\/doi.org\/10.1038\/sj.leu.2405068.","journal-title":"Leukemia"},{"issue":"3","key":"1293_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00428-015-1858-9","volume":"468","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468(3):259\u201375. https:\/\/doi.org\/10.1007\/s00428-015-1858-9.","journal-title":"Virchows Arch"},{"issue":"1","key":"1293_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cncr.27704","volume":"119","author":"A Heilgeist","year":"2013","unstructured":"Heilgeist A, et al. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer. 2013;119(1):99\u2013106. https:\/\/doi.org\/10.1002\/cncr.27704.","journal-title":"Cancer"},{"issue":"17","key":"1293_CR45","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","volume":"127","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, et al. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072\u201381. https:\/\/doi.org\/10.1182\/blood-2015-11-624312.","journal-title":"Blood"},{"issue":"4","key":"1293_CR46","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s11307-023-01830-9","volume":"25","author":"A Kosmala","year":"2023","unstructured":"Kosmala A, et al. Lymphoma-sink effect in marginal zone lymphoma based on CXCR4-targeted molecular imaging. Mol Imaging Biol. 2023;25(4):758\u201364. https:\/\/doi.org\/10.1007\/s11307-023-01830-9.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"1293_CR47","first-page":"92","volume":"26","author":"A Traverse-Glehen","year":"2012","unstructured":"Traverse-Glehen A, et al. Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. Oncology (Williston Park). 2012;26(1):92\u20139 (103-4).","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"1293_CR48","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365. https:\/\/doi.org\/10.1182\/blood-2003-12-4434.","journal-title":"Blood"},{"issue":"6","key":"1293_CR49","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ajh.20874","volume":"82","author":"SY Oh","year":"2007","unstructured":"Oh SY, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol. 2007;82(6):446\u201352. https:\/\/doi.org\/10.1002\/ajh.20874.","journal-title":"Am J Hematol"},{"issue":"27","key":"1293_CR50","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/jco.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362. https:\/\/doi.org\/10.1200\/jco.2008.21.3991.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1293_CR51","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409\u201317. https:\/\/doi.org\/10.1182\/blood-2017-03-771915.","journal-title":"Blood"},{"issue":"1","key":"1293_CR52","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijrobp.2015.01.040","volume":"92","author":"S Teckie","year":"2015","unstructured":"Teckie S, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92(1):130\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1293_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3109\/10428194.2013.818143","volume":"55","author":"C Montalban","year":"2014","unstructured":"Montalban C, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma. 2014;55(4):929\u201331. https:\/\/doi.org\/10.3109\/10428194.2013.818143.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1293_CR54","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3109\/10428194.2014.897703","volume":"55","author":"C Kalpadakis","year":"2014","unstructured":"Kalpadakis C, et al. Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. Leuk Lymphoma. 2014;55(11):2640\u20132. https:\/\/doi.org\/10.3109\/10428194.2014.897703.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1293_CR55","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1080\/10428194.2019.1594212","volume":"60","author":"M Sorigue","year":"2019","unstructured":"Sorigue M, et al. Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leuk Lymphoma. 2019;60(10):2524\u201331. https:\/\/doi.org\/10.1080\/10428194.2019.1594212.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1293_CR56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2141.2006.06437.x","volume":"136","author":"L Arcaini","year":"2007","unstructured":"Arcaini L, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007;136(2):301\u20134. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06437.x.","journal-title":"Br J Haematol"},{"key":"1293_CR57","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.eclinm.2024.102592","volume":"72","author":"L Arcaini","year":"2024","unstructured":"Arcaini L, et al. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine. 2024;72:102592. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102592.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1293_CR58","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/annonc\/mdt507","volume":"25","author":"AH Meyer","year":"2014","unstructured":"Meyer AH, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol. 2014;25(1):210\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdt507.","journal-title":"Ann Oncol"},{"issue":"23","key":"1293_CR59","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1182\/bloodadvances.2024013188","volume":"8","author":"C Bommier","year":"2024","unstructured":"Bommier C, et al. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv. 2024;8(23):5939\u201348. https:\/\/doi.org\/10.1182\/bloodadvances.2024013188.","journal-title":"Blood Adv"},{"issue":"5","key":"1293_CR60","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1080\/10428194.2020.1855347","volume":"62","author":"J Poveda","year":"2021","unstructured":"Poveda J, et al. Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma. Leuk Lymphoma. 2021;62(5):1116\u201322. https:\/\/doi.org\/10.1080\/10428194.2020.1855347.","journal-title":"Leuk Lymphoma"},{"key":"1293_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2023.08.004","author":"T Stueber","year":"2023","unstructured":"Stueber T, et al. The clinical significance of increased large cells in marginal zone lymphoma. Hum Pathol. 2023. https:\/\/doi.org\/10.1016\/j.humpath.2023.08.004.","journal-title":"Hum Pathol"},{"issue":"6","key":"1293_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/jcp-2022-208603","volume":"77","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Clinicopathological features of CD5-positive splenic marginal zone lymphoma. J Clin Pathol. 2024;77(6):421\u20135. https:\/\/doi.org\/10.1136\/jcp-2022-208603.","journal-title":"J Clin Pathol"},{"issue":"10","key":"1293_CR63","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","volume":"134","author":"S Luminari","year":"2019","unstructured":"Luminari S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134(10):798\u2013801. https:\/\/doi.org\/10.1182\/blood.2019001088.","journal-title":"Blood"},{"issue":"10","key":"1293_CR64","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1016\/s2665-9913(24)00198-x","volume":"6","author":"J Rocca","year":"2024","unstructured":"Rocca J, et al. Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sj\u00f6gren\u2019s disease activity: a multicentre, retrospective, observational study. Lancet Rheumatol. 2024;6(10):e703\u201312. https:\/\/doi.org\/10.1016\/s2665-9913(24)00198-x.","journal-title":"Lancet Rheumatol"},{"key":"1293_CR65","doi-asserted-by":"publisher","first-page":"6794848","DOI":"10.1155\/2016\/6794848","volume":"2016","author":"JS Kim","year":"2016","unstructured":"Kim JS, et al. Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according to H. pylori infection status. Gastroenterol Res Pract. 2016;2016:6794848. https:\/\/doi.org\/10.1155\/2016\/6794848.","journal-title":"Gastroenterol Res Pract"},{"issue":"24","key":"1293_CR66","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/jco.2011.41.4466","volume":"30","author":"AJ Ferreri","year":"2012","unstructured":"Ferreri AJ, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988\u201394. https:\/\/doi.org\/10.1200\/jco.2011.41.4466.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1293_CR67","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3109\/10428194.2014.975801","volume":"56","author":"IS Lossos","year":"2015","unstructured":"Lossos IS, et al. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015;56(6):1750\u20135. https:\/\/doi.org\/10.3109\/10428194.2014.975801.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"1293_CR68","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/jco.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"Zucca E, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905\u201312. https:\/\/doi.org\/10.1200\/jco.2016.70.6994.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1293_CR69","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bjh.15641","volume":"183","author":"E Iannitto","year":"2018","unstructured":"Iannitto E, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study. Br J Haematol. 2018;183(5):755\u201365. https:\/\/doi.org\/10.1111\/bjh.15641.","journal-title":"Br J Haematol"},{"issue":"4","key":"1293_CR70","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","volume":"91","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012;91(4):543\u201351. https:\/\/doi.org\/10.1007\/s00277-011-1337-6.","journal-title":"Ann Hematol"},{"issue":"6","key":"1293_CR71","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","volume":"145","author":"JR Brown","year":"2009","unstructured":"Brown JR, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145(6):741\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07677.x.","journal-title":"Br J Haematol"},{"issue":"14","key":"1293_CR72","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/jco.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399. https:\/\/doi.org\/10.1200\/jco.19.00010.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1293_CR73","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393. https:\/\/doi.org\/10.1016\/s1470-2045(16)30097-3.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1293_CR74","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/jco.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395\u2013404. https:\/\/doi.org\/10.1200\/jco.2017.76.8960.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1293_CR75","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/bjh.15454","volume":"182","author":"I Avivi","year":"2018","unstructured":"Avivi I, et al. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. Br J Haematol. 2018;182(6):807\u201315. https:\/\/doi.org\/10.1111\/bjh.15454.","journal-title":"Br J Haematol"},{"issue":"5","key":"1293_CR76","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3324\/haematol.2008.001537","volume":"94","author":"M Troch","year":"2009","unstructured":"Troch M, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94(5):738\u201342. https:\/\/doi.org\/10.3324\/haematol.2008.001537.","journal-title":"Haematologica"},{"issue":"16","key":"1293_CR77","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"A Noy","year":"2017","unstructured":"Noy A, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood. 2017;129(16):2224\u201332. https:\/\/doi.org\/10.1182\/blood-2016-10-747345.","journal-title":"Blood"},{"issue":"22","key":"1293_CR78","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","volume":"7","author":"S Opat","year":"2023","unstructured":"Opat S, et al. Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv. 2023;7(22):6801\u201311. https:\/\/doi.org\/10.1182\/bloodadvances.2023010668.","journal-title":"Blood Adv"},{"issue":"1","key":"1293_CR79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.18368","volume":"199","author":"P Strati","year":"2022","unstructured":"Strati P, et al. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022;199(1):76\u201385. https:\/\/doi.org\/10.1111\/bjh.18368.","journal-title":"Br J Haematol"},{"issue":"11","key":"1293_CR80","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ajh.27064","volume":"98","author":"L Deng","year":"2023","unstructured":"Deng L, et al. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. Am J Hematol. 2023;98(11):1742\u201350. https:\/\/doi.org\/10.1002\/ajh.27064.","journal-title":"Am J Hematol"},{"issue":"10277","key":"1293_CR81","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901. https:\/\/doi.org\/10.1016\/s0140-6736(21)00224-5.","journal-title":"Lancet"},{"issue":"11","key":"1293_CR82","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1314583.","journal-title":"N Engl J Med"},{"issue":"11","key":"1293_CR83","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/jco.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37(11):912\u201322. https:\/\/doi.org\/10.1200\/jco.18.00915.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1293_CR84","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169\u201378. https:\/\/doi.org\/10.1093\/annonc\/mdx289.","journal-title":"Ann Oncol"},{"issue":"16","key":"1293_CR85","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","volume":"133","author":"A Forero-Torres","year":"2019","unstructured":"Forero-Torres A, et al. Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133(16):1742\u201352. https:\/\/doi.org\/10.1182\/blood-2018-08-867499.","journal-title":"Blood"},{"issue":"17","key":"1293_CR86","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.Ccr-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids MS, et al. Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study. Clin Cancer Res. 2021;27(17):4690\u20135. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4842.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1293_CR87","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","volume":"29","author":"S de Vos","year":"2018","unstructured":"de Vos S, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy256.","journal-title":"Ann Oncol"},{"issue":"17","key":"1293_CR88","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","volume":"127","author":"E Zucca","year":"2016","unstructured":"Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17):2082\u201392. https:\/\/doi.org\/10.1182\/blood-2015-12-624304.","journal-title":"Blood"},{"issue":"16","key":"1293_CR89","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/j.ejca.2008.07.005","volume":"44","author":"LG Capelle","year":"2008","unstructured":"Capelle LG, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44(16):2470\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2008.07.005.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1293_CR90","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1053\/j.gastro.2012.06.035","volume":"143","author":"T W\u00fcndisch","year":"2012","unstructured":"W\u00fcndisch T, et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology. 2012;143(4):936\u201342. https:\/\/doi.org\/10.1053\/j.gastro.2012.06.035. (quiz e13-4).","journal-title":"Gastroenterology"},{"key":"1293_CR91","doi-asserted-by":"publisher","first-page":"a1454","DOI":"10.1136\/bmj.a1454","volume":"337","author":"L Fuccio","year":"2008","unstructured":"Fuccio L, et al. Treatment of helicobacter pylori infection. Bmj. 2008;337:a1454. https:\/\/doi.org\/10.1136\/bmj.a1454.","journal-title":"Bmj"},{"issue":"1","key":"1293_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjh.12078","volume":"160","author":"C Copie-Bergman","year":"2013","unstructured":"Copie-Bergman C, et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol. 2013;160(1):47\u201352. https:\/\/doi.org\/10.1111\/bjh.12078.","journal-title":"Br J Haematol"},{"issue":"4","key":"1293_CR93","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","volume":"61","author":"S Nakamura","year":"2012","unstructured":"Nakamura S, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507\u201313. https:\/\/doi.org\/10.1136\/gutjnl-2011-300495.","journal-title":"Gut"},{"issue":"28","key":"1293_CR94","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1200\/jco.2005.04.031","volume":"23","author":"P Koch","year":"2005","unstructured":"Koch P, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02\/96). J Clin Oncol. 2005;23(28):7050\u20139. https:\/\/doi.org\/10.1200\/jco.2005.04.031.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1293_CR95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17\u201329. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.010.","journal-title":"Ann Oncol"},{"issue":"9","key":"1293_CR96","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1093\/annonc\/mdt181","volume":"24","author":"G Cervetti","year":"2013","unstructured":"Cervetti G, et al. Significant efficacy of 2-chlorodeoxyadenosine{+\/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Ann Oncol. 2013;24(9):2434\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdt181.","journal-title":"Ann Oncol"},{"issue":"2","key":"1293_CR97","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","volume":"18","author":"C Kalpadakis","year":"2013","unstructured":"Kalpadakis C, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18(2):190\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2012-0251.","journal-title":"Oncologist"},{"issue":"1\u20132","key":"1293_CR98","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.beha.2016.07.004","volume":"30","author":"C Kalpadakis","year":"2017","unstructured":"Kalpadakis C, et al. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30(1\u20132):139\u201348. https:\/\/doi.org\/10.1016\/j.beha.2016.07.004.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"1293_CR99","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","volume":"55","author":"C Kalpadakis","year":"2014","unstructured":"Kalpadakis C, et al. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma. 2014;55(7):1463\u201370. https:\/\/doi.org\/10.3109\/10428194.2013.845884.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1293_CR100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.beha.2017.10.011","volume":"31","author":"C Kalpadakis","year":"2018","unstructured":"Kalpadakis C, et al. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma? Best Pract Res Clin Haematol. 2018;31(1):65\u201372. https:\/\/doi.org\/10.1016\/j.beha.2017.10.011.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"1293_CR101","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","volume":"132","author":"C Kalpadakis","year":"2018","unstructured":"Kalpadakis C, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666\u201370. https:\/\/doi.org\/10.1182\/blood-2018-02-833608.","journal-title":"Blood"},{"issue":"8776","key":"1293_CR102","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/0140-6736(91)92035-z","volume":"338","author":"AC Wotherspoon","year":"1991","unstructured":"Wotherspoon AC, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338(8776):1175\u20136. https:\/\/doi.org\/10.1016\/0140-6736(91)92035-z.","journal-title":"Lancet"},{"issue":"2","key":"1293_CR103","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","volume":"8","author":"A Zullo","year":"2010","unstructured":"Zullo A, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8(2):105\u201310. https:\/\/doi.org\/10.1016\/j.cgh.2009.07.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1293_CR104","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/cancers14071742","volume":"14","author":"A Di Rocco","year":"2022","unstructured":"Di Rocco A, et al. Extranodal marginal zone lymphoma: pathogenesis, diagnosis and treatment. Cancers (Basel). 2022;14(7):1742. https:\/\/doi.org\/10.3390\/cancers14071742.","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"1293_CR105","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.beha.2017.01.002","volume":"30","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Zucca E. Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best Pract Res Clin Haematol. 2017;30(1\u20132):109\u201317. https:\/\/doi.org\/10.1016\/j.beha.2017.01.002.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"1293_CR106","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","volume":"122","author":"B Kiesewetter","year":"2013","unstructured":"Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122(8):1350\u20137. https:\/\/doi.org\/10.1182\/blood-2013-02-486522.","journal-title":"Blood"},{"issue":"2","key":"1293_CR107","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"O Hermine","year":"2002","unstructured":"Hermine O, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89\u201394. https:\/\/doi.org\/10.1056\/NEJMoa013376.","journal-title":"N Engl J Med"},{"issue":"7","key":"1293_CR108","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","volume":"25","author":"L Arcaini","year":"2014","unstructured":"Arcaini L, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdu166.","journal-title":"Ann Oncol"},{"issue":"1","key":"1293_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.2021.278755","volume":"107","author":"CY Cheah","year":"2022","unstructured":"Cheah CY, et al. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022;107(1):35\u201343. https:\/\/doi.org\/10.3324\/haematol.2021.278755.","journal-title":"Haematologica"},{"issue":"1","key":"1293_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom J, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):11\u201331. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.009.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1123","key":"1293_CR111","doi-asserted-by":"publisher","first-page":"20210012","DOI":"10.1259\/bjr.20210012","volume":"94","author":"M Cerrato","year":"2021","unstructured":"Cerrato M, et al. Efficacy of low-dose radiotherapy (2 Gy \u00d7 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas. Br J Radiol. 2021;94(1123):20210012. https:\/\/doi.org\/10.1259\/bjr.20210012.","journal-title":"Br J Radiol"},{"issue":"5","key":"1293_CR112","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/annonc\/mds623","volume":"24","author":"A Wirth","year":"2013","unstructured":"Wirth A, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol. 2013;24(5):1344\u201351. https:\/\/doi.org\/10.1093\/annonc\/mds623.","journal-title":"Ann Oncol"},{"issue":"1","key":"1293_CR113","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1293_CR114","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2016-05-714584","volume":"129","author":"A Desai","year":"2017","unstructured":"Desai A, et al. Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood. 2017;129(3):324\u201332. https:\/\/doi.org\/10.1182\/blood-2016-05-714584.","journal-title":"Blood"},{"issue":"2","key":"1293_CR115","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.13021","volume":"167","author":"F Samaniego","year":"2014","unstructured":"Samaniego F, et al. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014;167(2):207\u201313. https:\/\/doi.org\/10.1111\/bjh.13021.","journal-title":"Br J Haematol"},{"issue":"7","key":"1293_CR116","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","volume":"20","author":"T Al Juhaishi","year":"2019","unstructured":"Al Juhaishi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin\u2019s lymphoma: does one size fit all? Expert Opin Pharmacother. 2019;20(7):773\u20135. https:\/\/doi.org\/10.1080\/14656566.2019.1582643.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"1293_CR117","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","volume":"102","author":"A Conconi","year":"2003","unstructured":"Conconi A, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102(8):2741\u20135. https:\/\/doi.org\/10.1182\/blood-2002-11-3496.","journal-title":"Blood"},{"issue":"5","key":"1293_CR118","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/bjh.15843","volume":"185","author":"MR Becnel","year":"2019","unstructured":"Becnel MR, et al. Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185(5):874\u201382. https:\/\/doi.org\/10.1111\/bjh.15843.","journal-title":"Br J Haematol"},{"issue":"30","key":"1293_CR119","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/jco.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-hodgkin lymphoma: final analysis of the GAUSS Study. J Clin Oncol. 2015;33(30):3467\u201374. https:\/\/doi.org\/10.1200\/jco.2014.59.2139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1293_CR120","doi-asserted-by":"publisher","first-page":"565","DOI":"10.12998\/wjcc.v12.i3.565","volume":"12","author":"SJ Bai","year":"2024","unstructured":"Bai SJ, et al. Marginal zone lymphoma with severe rashes: a case report. World J Clin Cases. 2024;12(3):565\u201374. https:\/\/doi.org\/10.12998\/wjcc.v12.i3.565.","journal-title":"World J Clin Cases"},{"issue":"3","key":"1293_CR121","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/s2352-3026(14)00021-0","volume":"1","author":"A Salar","year":"2014","unstructured":"Salar A, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3):e104\u201311. https:\/\/doi.org\/10.1016\/s2352-3026(14)00021-0.","journal-title":"Lancet Haematol"},{"issue":"15","key":"1293_CR122","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","volume":"130","author":"A Salar","year":"2017","unstructured":"Salar A, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130(15):1772\u20134. https:\/\/doi.org\/10.1182\/blood-2017-07-795302.","journal-title":"Blood"},{"issue":"3","key":"1293_CR123","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","volume":"144","author":"BW Hancock","year":"2009","unstructured":"Hancock BW, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009;144(3):367\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07486.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"1293_CR124","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5045\/br.2017.52.3.200","volume":"52","author":"J Seo","year":"2017","unstructured":"Seo J, et al. Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Res. 2017;52(3):200\u20136. https:\/\/doi.org\/10.5045\/br.2017.52.3.200.","journal-title":"Blood Res"},{"issue":"1","key":"1293_CR125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40880-019-0403-7","volume":"39","author":"SY Oh","year":"2019","unstructured":"Oh SY, et al. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Commun (Lond). 2019;39(1):58. https:\/\/doi.org\/10.1186\/s40880-019-0403-7.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"1293_CR126","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","volume":"129","author":"B Kiesewetter","year":"2017","unstructured":"Kiesewetter B, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;129(3):383\u20135. https:\/\/doi.org\/10.1182\/blood-2016-06-720599.","journal-title":"Blood"},{"issue":"1","key":"1293_CR127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cncr.11893","volume":"100","author":"L Arcaini","year":"2004","unstructured":"Arcaini L, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100(1):107\u201315. https:\/\/doi.org\/10.1002\/cncr.11893.","journal-title":"Cancer"},{"issue":"6","key":"1293_CR128","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000098555","volume":"70","author":"M Raderer","year":"2006","unstructured":"Raderer M, et al. Activity of rituximab plus cyclophosphamide, doxorubicin\/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology. 2006;70(6):411\u20137. https:\/\/doi.org\/10.1159\/000098555.","journal-title":"Oncology"},{"issue":"22","key":"1293_CR129","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","volume":"4","author":"A Noy","year":"2020","unstructured":"Noy A, et al. Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4(22):5773\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2020003121.","journal-title":"Blood Adv"},{"issue":"6","key":"1293_CR130","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.35114","volume":"130","author":"MJ Gordon","year":"2024","unstructured":"Gordon MJ, et al. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: an open label, phase 2 study. Cancer. 2024;130(6):876\u201385. https:\/\/doi.org\/10.1002\/cncr.35114.","journal-title":"Cancer"},{"issue":"22","key":"1293_CR131","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","volume":"7","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil LJ, et al. Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023;7(22):7141\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2023010298.","journal-title":"Blood Adv"},{"issue":"15","key":"1293_CR132","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/jco.20.03433","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, et al. Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39(15):1609\u201318. https:\/\/doi.org\/10.1200\/jco.20.03433.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1293_CR133","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1002\/cncr.34366","volume":"128","author":"A Hollebecque","year":"2022","unstructured":"Hollebecque A, et al. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022;128(17):3185\u201395. https:\/\/doi.org\/10.1002\/cncr.34366.","journal-title":"Cancer"},{"issue":"6","key":"1293_CR134","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506. https:\/\/doi.org\/10.1182\/blood.2023021243.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01293-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01293-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:26:20Z","timestamp":1739935580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01293-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01293-w","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"8 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}